Mergers & Acquisitions - Financial, Neurological

Filter

Current filters:

FinancialNeurological

Popular Filters

Aphios spins off Amylon to develop novel Alzheimer’s disease drug

21-11-2013

US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

Elan sells its Tysabri rights to Biogen; posts 2012 financials

07-02-2013

Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

Illumina to buy Verinata; Rusnano et al invest in Marinus

08-01-2013

USA-based Illumina (Nasdaq: ILMN), recently the subject of a failed takeover bid by Swiss drug major…

Domain AssociatesFinancialganaxoloneIlluminaMarinus PharmaceuticalsMergers & AcquisitionsNeurologicalPharmaceuticalResearchRusNanoVerinata Health

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal

07-09-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Company Spotlight

ImmunoGen

ImmunoGen

Back to top